

Pam Rajendran Taub, MD, FACC, FASPC
 Cardiologist/Professor of Medicine
 Founder and Director of Step Family Cardiac Wellness and Rehabilitation Center
 Division of Cardiovascular Medicine, Department of Medicine
 University of California, San Diego
 9300 Campus Point Dr., MC7414
 La Jolla, CA, 92037
www.taubresearchgroup.ucsd.edu
 858-822-8095 mobile
 858- 249-1308 work
 858-249-1309 fax
 ptaub@ucsd.edu



4/16/23

EDUCATION

- 9/98 – 5/03 **Boston University School of Medicine, M.D., 2003**
- Member, Alpha Omega Alpha (AOA)
- 9/94 – 5/98 **Boston University, B.A., 1998; Major: Psychology; Grade Point Average: 3.7/4.0 (*magna cum laude*)**
- Boston University Trustee Scholar (Four Year Full Tuition Merit Scholarship)
 - Independent Study with Nobel Peace Prize Winner Elie Wiesel

POSTGRADUATE TRAINING

- 7/07 – 6/10 **University of California San Diego (UCSD), San Diego, CA**
 Fellow, Division of Cardiovascular Medicine (Chief Cardiology Fellow 2009-2010)
- 7/05 – 6/07 **University of Washington, Seattle, WA**
 Resident Physician, Department of Medicine
- 7/04 – 6/05 **University of California San Francisco (USCF), San Francisco, CA**
 Resident Physician, Department of Neurology
- 6/03 – 6/04 **Virginia Mason Medical Center, Seattle, WA**
 Intern, Department of Medicine

MEDICAL LICENSURE/BOARD CERTIFICATION

- 2004 – present California (Full Physician License: A89612)
- 2007 – 2027 Board Certified in Internal Medicine, American Board of Internal Medicine
- 2011-2024 Board Certified in Cardiovascular Disease, American Board of Internal Medicine
- 2016-2024 Fluoroscopy Permit (RHC 00166856)

EXPERIENCE

- 7/10 to Present **University of California, San Diego (UCSD), Division of Cardiovascular Medicine**
Professor of Medicine (July 2021– Present)
 Associate Professor of Medicine (July 2015 – June 2021)
 Assistant Professor of Medicine (July 2010 –June 2015)
 Founding Director of Step Family Cardiac Wellness and Rehabilitation Center (January 2015 – Present)

❖ **Clinical /Teaching**

- Clinical responsibilities include serving as attending physician on Coronary Care Unit, Cardiology Consult Service, and outpatient cardiology clinic (I have 5 half-day outpatient clinic sessions per week and one half-day of reading echocardiograms/stress tests).
- My clinical practice focuses on preventive cardiology, and I have translated unmet needs observed in my clinical practice to the realm of clinical research.
- I am extensively involved with teaching medical students, residents, and fellows and have an established track record of mentoring trainees.

❖ **Research**

- My research focuses on assessing the impact of behavioral, technological, and pharmacological interventions on cardiometabolic diseases. My funding includes NIH (Principal Investigator on RO1), American Heart Association, Department of Defense, and Department of Homeland Security.
- I have devoted my career to examining mitochondrial dysfunction from many perspectives. My research integrates molecular and ultrastructural changes in mitochondria with important clinical parameters such as VO₂ max. I have expertise in performing skeletal muscle biopsies and with techniques of assessing mitochondrial structure/function. I have studied the impact of epicatechin (a flavanol in cocoa) in improving mitochondrial function. Through multiple clinical trials, I have gathered novel data on the beneficial effects of epicatechin in improving mitochondrial structure and function and in stimulating mitochondrial biogenesis. Based on this data, I co-founded a pharmaceutical company (Epirium Bio) which is in early-stage clinical trials with derivatives of epicatechin.
- I am currently examining the effects of time-restricted eating (TRE) on mitochondrial function in patients with metabolic syndrome and Type II Diabetes. I have extensive experience conducting clinical trials and served as the Principal Investigator on multiple clinical trials, including two recent trials that have resulted in important clinical observations on the beneficial impact of TRE in patients with metabolic syndrome (NCT03182985) and firefighter shift workers (NCT03533023).
- I am widely published (with over 100 publications, book chapters) with high impact publications in top peer-reviewed journals including *Cell Metabolism* and the *Journal of the American College of Cardiology*.

❖ **National/International Clinical Trial Leadership**

- US National Lead/Steering Committee Member for: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P). (Sponsor: Novartis; NCT05030428)
- US National Lead/Steering Committee Member for: A Double-blind, Randomized, Placebo controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a). (Sponsor: Amgen; NCT05581303)
- US National Lead/Steering Committee Member for Phase 3 Trial of oral PCSK9 Inhibitor (MK-0616). (Sponsor: Merck)
- Executive Steering Committee Member for VICTORIAN-1P Trial (Sponsor: Novartis)
- National Principal Investigator for the NIH RECOVER COVID Initiative (recovercovid.org) and responsible for design and execution of studies related to Post COVID Postural Orthostatic Tachycardia Syndrome.
- Executive Steering Committee Member for Cleerly Health's Primary Prevention Coronary CT Angiography (TRANSFORM) Trial.

❖ **Leadership/Administrative Duties**

- I am the Director and Founder of the Step Family Cardiac Wellness and Rehabilitation Center which opened for patient care in January 2018 and is one of the largest cardiac rehabilitation programs in the US. I have been responsible for all aspects of the center from design of the space to developing programs for patients. The center is actively engaging patients and the community in prevention of cardiovascular disease.

- I am a member of the UCSD Cardiovascular Institute (CVI) Cabinet which is the governing body for the CVI and responsible for all major decisions and strategic initiatives.

- 1/05 – 6/07 **University of California, San Francisco (UCSF)**, Division of Cardiology
Conducted research assessing cardiovascular predictors of mortality in subarachnoid hemorrhage and the role of endothelial nitric oxide polymorphisms and the risk of cerebral vasospasm.
Responsible for data collection, study design, and manuscript writing.
- 3/00 – 6/02 **Journal of the American Medical Association (JAMA)**, Chicago, IL
Deputy Editor (2001-2002) and *Associate Editor* (2000-2001)
Spearheaded all aspects of production such as formulating theme of issue, soliciting and editing manuscripts of 7-page monthly medical student section in JAMA.
- 7/00 – 3/01 **Massachusetts Institute of Technology**, Department of Brain and Cognitive Science, Cambridge, MA
Designed original clinical research to assess the effects of age at onset of Parkinson's disease on working memory.
Responsible for project design, subject recruitment, data collection/analysis, and manuscript writing.
Awarded grants from:
 - American Parkinson Disease Association (medical student research grant)
 - American Federation for Aging Research (medical student scholarship)
 - The American Academy of Neurology (medical student research grant)
 - Parkinson's Disease Foundation (medical student research fellowship)
- Summer 1999 **Johns Hopkins University School of Medicine**, Department of Neurology, Baltimore, MD
Designed original research project to assess the use of alternative medicines in patients with Parkinson's disease.
Responsible for study design, recruitment of 201 patients, data collection/analysis, and manuscript writing.
- Summer 1998 **National Sleep Foundation**, Washington D.C.
Authored nationally distributed brochure on sleep problems unique to women. Co-developed the largest national poll administered to women on sleep issues.
- 9/97 – 12/97 **Lehman Brothers**, Pharmaceutical Research Group, London, England
Forecasted drug sales by analyzing drug efficacy, and authored report on drugs in development for the treatment of dementia.

BIBLIOGRAPHY

Published Articles in Peer Reviewed Journals (* denotes article in which mentee is the first author)

- 1. Epicatechin's effect on skeletal muscle and mitochondrial function:** These studies elucidate the role of epicatechin (a flavanol) on mitochondria and demonstrate the beneficial effects of epicatechin upon mitochondria structure and function, analyzed via assessment of skeletal muscle changes and mitochondrial protein levels. This work resulted in two granted US patents. The results of these studies have broad clinical applications and led to the founding of a pharmaceutical company (Epirium Bio) that is developing drugs for the treatment of mitochondrial disorders.
 - 1) Yamazaki KG, **Taub PR**, Barraza-Hidalgo M, Rivas MM, Zambon AC, Ceballos G, Villarreal FJ. Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion. *J Am Coll Cardiol.* 2010;55(25):2869-76 (PMID: 20579545, PMCID: PMC2915587).
 - 2) Nogueira L, Ramirez-Sanchez I, Perkins GA, Murphy A, **Taub PR**, Ceballos G, Villarreal FJ, Hogan MC, Malek MH. (-)-Epicatechin enhances fatigue resistance and oxidative capacity in mouse muscle. *J Physiol.* 2011;589(Pt 18):4615-31 (PMID: 21788351, PMCID: PMC3208228).

- 3) **Taub PR**, Ramirez-Sanchez I, Ciaraldi TP, Perkins G, Murphy AN, Naviaux R, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. *Clin Transl Sci*. 2012;5(1):43-7 (PMID: 22376256, PMCID: PMC5439909).
- 4) Ramirez-Sanchez I*, Nogueira L, Morena A, Murphy A, **Taub PR**, Perkins G, Ceballos G, Hogan M, Malek MH, Villarreal F. Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa. *J Cardiovasc Pharmacol*. 2012;60:429-38 (PMID: 22833114, PMCID: PMC3496054).
- 5) Ramirez-Sanchez I*, **Taub PR**, Ciaraldi TP, Nogueira L, Coe T, Perkins G, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. (-)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients. *Int J Cardiol*. 2013;168(4):3982-90 (PMID: 23870648, PMCID: PMC3805662).
- 6) **Taub PR**, Ramirez-Sanchez I, Ciaraldi T, Gonzalez-Basurto S, Coral-Vazquez R, Perkins G, Hogan M, Maisel A, Henry R, Ceballos G, Villarreal F. Severe perturbations in skeletal muscle sarcomere structure of heart failure and type 2 diabetes patients: Restorative effects of (-)-epicatechin-rich cocoa. *Clin Sci*. 2013;125:383-89 (PMID: 23642227, PMCID: PMC3805662).
- 7) Gutierrez-Salmean G, Ciaraldi T, Nogueira L, **Taub PR**, Hogan M, Henry R, Meany E, Villarreal F, Ceballos G, Ramirez-Sanchez I. Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation. *J Nut Biochem*. 2013;25:91-4 (PMID: 2431487, PMCID: PMC3857584).
- 8) Ortiz-Vilchis P, Yamazaki KG, Rubio-Gayosso I, Ramirez-Sanchez I, Calzada C, Romero-Perez D, Ortiz A, Meany E, **Taub PR**, Villarreal F, Ceballos G. Co-administration of the flavanol (-)-epicatechin with doxycycline synergistically reduces infarct size in a model of ischemia reperfusion injury by inhibition of mitochondrial swelling. *Eur J Pharmacol*. 2014;744:76-82 (PMID: 25281837, PMCID: PMC5109834).
- 9) Barnett CF, Moreno-Ulloa A, Shiva S, Ramirez-Sanchez I, **Taub PR**, Su Y, Ceballos G, Dugar S, Schreiner G, Villarreal F. Pharmacokinetic, partial pharmacodynamics and initial safety analysis of (-)-epicatechin in healthy volunteers. *Food Funct*. 2015;6(3):824-33 (PMID: 25598082, PMCID: PMC4357542).
- 10) **Taub PR**, Ramirez-Sanchez I, Patel M, Higginbotham E, Moreno-Ulloa A, Roman L, Phillips P, Ceballos G, Villarreal F. Beneficial effects of dark chocolate on exercise capacity in sedentary subjects: Underlying mechanisms. A double blind, randomized, placebo-controlled trial. *Food Funct*. 2016;7(9):3686-93. (PMID: 27491778, PMCID: PMC5025384).
- 11) Gutierrez-Salmean G, Meany E, Lanaspá MA, Cicerchi C, Johnson RJ, Dugar S, **Taub PR**, Ramirez-Sanchez I, Villarreal F, Schreiner G, Ceballos G. A randomized, placebo-controlled, double-blind study on the effects of (-)-epicatechin on the triglyceride/HDLc ratio and cardiometabolic profile of subjects with hypertriglyceridemia: unique in vitro effects. *Int J Cardiol*. 2016; 223:500-506 (PMID: 27552564).
- 12) Formentini L, Ryan AJ, Gálvez-Santisteban M, Carter L, **Taub P**, Lapek JD Jr, Gonzalez DJ, Villarreal F, Ciaraldi TP, Cuezva JM, Henry RR. Mitochondrial H⁺-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance. *Diabetologia*. 2017;60(10):2052-2065 (PMID: 28770317, PMCID: PMC6572787).
- 13) Moreno-Ulloa A, Nájera-García N, Hernández M, Ramírez-Sánchez I, **Taub PR**, Su Y, Beltrán-Partida E, Ceballos G, Dugar S, Schreiner G, Best BM, Ciaraldi TP, Henry RR, Villarreal F. A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints. *Food Funct*. 2018;9(1):307-319 (PMID: 29171848, PMCID: PMC5783763).

2. Cardiometabolic Effects of Time-Restricted Eating: I have led clinical trials demonstrating that time restricted eating can improve cardiometabolic risk factors. The findings from our trials are now being incorporated into clinical practice and in expert recommendations (e.g. American Society of Preventive Cardiology) for patients with cardiovascular risk factors such as metabolic syndrome and obesity.

- 14) Sulli G, Manoogian ENC, **Taub PR**, Panda S. Training the Circadian Clock, Clocking the Drugs, and Drugging the Clock to Prevent, Manage, and Treat Chronic Diseases. *Trends Pharmacol Sci*. 2018;pii: S0165-6147(18)30119-6 (PMID: 30060890).
- 15) Wilkinson MJ*, Manoogian ENC, Zadourian A, Lo H, Fakhouri S, Shoghi A, Wang X, Fleischer JG, Navlakha S, Panda S, **Taub PR**. Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome. *Cell Metab*. 2020;31(1):92-104.e5 (PMID: 31813824; PMCID: PMC6953486).

- 16) Dong TA*, Sandesara PB, Dhindsa DS, Mehta A, Arneson LC, Dollar AL, **Taub PR**, Sperling LS. Intermittent Fasting: A Heart Healthy Dietary Pattern? *Am J Med.* 2020; S0002-9343(20)30335-1 (PMID: 32330491).
- 17) Świątkiewicz I*; Woźniak A, **Taub PR**. Time-Restricted Eating and Metabolic Syndrome: Current Status and Future Perspectives. *Nutrients.* 2021;13(1):221 (PMID: 33466692).
- 18) Świątkiewicz I*, Mila-Kierzenkowska C, Woźniak A, Szewczyk-Golec K, Nuskiewicz J, Wróblewska J, Rajewski P, Eussen SJPM, Færch K, Manoogian ENC, Panda S, **Taub PR**. Pilot Clinical Trial of Time-Restricted Eating in Patients with Metabolic Syndrome. *Nutrients.* 2021 Jan 24;13(2):346. PMID: 33498955.
- 19) Manoogian ENC*, Zadourian A*, Lo HC*, Gutierrez NR, Shoghi A, Rosander A, Pazargadi A, Wang X, Fleischer JG, Golshan S, **Taub PR**, Panda S. Protocol for a randomised controlled trial on the feasibility and effects of 10-hour time-restricted eating on cardiometabolic disease risk among career firefighters doing 24-hour shift work: the Healthy Heroes Study. *BMJ Open.* 2021;11(6):e045537 (PMID: 34135038).
- 20) Manoogian EN*, Chow LS, **Taub PR**, Laferrère B, Panda S. Time-restricted eating for the prevention and management of metabolic diseases. *Endocr Rev.* 2022;43(2):405-436. (PMID: 34550357).
- 21) **Taub PR**, Panda S. Time for better time-restricted eating trials to lessen the burden of metabolic diseases. *Cell Rep Med.* 2022 21;3(6):100665. P(MID: 35732151).
- 22) Manoogian ENC*, Zadourian A, Lo HC, Gutierrez NR., Shoghi A, Rosander A , Pazargadi A, Ormiston CK, Wang X, Sui J, Hou Z, Fleischer JG Golshan S, **Taub PR** and Panda S. Feasibility of Time-Restricted Eating and Impacts on Cardiometabolic Health in 24-Hour Shift Workers: The Healthy Heroes Randomized Clinical Trial. *Cell Metab.* 2022 4;34(10):1442-1456. (PMID 36198291)

3. Dysautonomia/Postural Orthostatic Tachycardia Syndrome (POTS): Conducted the first randomized clinical trial with ivabradine for patients with POTS. The findings from this study have been applied to an increasing number of patients with POTS after COVID-19 infection. This research has been highlighted by prominent news organizations including NPR and Medscape.

- 23) Zadourian A*, Doherty TA, Swiatkiewicz I*, and **Taub PR**. Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management. *Drugs.* 2018; 78(10):983-994 (PMID: 29943373).
- 24) **Taub PR**, Zadourian A*, Lo, H*, Ormiston C*, Golshan S, Hus JC. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia. *J Am Coll Cardiol.* 2021;77:861–7 (PMID: 33602468).
- 25) **Taub PR**, Zadourian A*, Hsu JC. Reply: Ivabradine in POTS: Increase in Central Pressure Rather Than Down-Regulation of Sympathetic Nervous System. *J Am Coll Cardiol.* 2021 Jun 22;77(24):3142-3143. PMID: 34140117.
- 26) Ocher RA*, Padilla E*, Hsu JC, **Taub PR**. Clinical and Laboratory Improvement in Hyperadrenergic Postural Orthostatic Tachycardia Syndrome (POTS) after COVID-19 Infection. *Case Rep Cardiol.* 2021 Aug 18;2021:7809231. PMID: 34471549.
- 27) Mittal N*, Portera A, **Taub P**. Improvement of hyperadrenergic postural orthostatic tachycardia syndrome (POTS) with methylated B vitamins in the setting of a heterozygous COMT Val158Met polymorphism. *BMJ Case Rep.* 2021 Nov 11;14(11):e245012. PMID: 34764114.
- 28) Gluckman TJ, Bhave NM, Allen LA, Chung EH, Spatz ES, Ammirati E, Baggish AL, Bozkurt B, Cornwell WK 3rd, Harmon KG, Kim JH, Lala A, Levine BD, Martinez MW, Onuma O, Phelan D, Puntmann VO, *J Am Coll Cardiol.* 2022 Mar; 14:S0735-1097.
- 29) Ormiston CK*, Padilla E, Van DT, Boone C, You S, Roberts AC, Hsiao A, **Taub PR**. May-Thurner syndrome in patients with postural orthostatic tachycardia syndrome and Ehlers-Danlos syndrome: a case series. *Eur Heart J Case Rep.* 2022 (PMID: 35620060) .
- 30) Ormiston CK*, Świątkiewicz I, **Taub PR**. Postural orthostatic tachycardia syndrome as a sequela of COVID-19. *Heart Rhythm.* 2022 Jul 16:S1547-5271(22)02185-3. (PMID: 35853576)

4. Biomarkers: These studies show the role of novel biomarkers in risk stratification of patients with cardiovascular and renal disease.

- 31) Ko N, **Rajendran PR**, Kim H, Rutowski M, Pawlikowska L, Kowk P, Higashida R, Lawton M, Smith W, Zaroff J, Young W. Endothelial nitric oxide synthase polymorphism and risk of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. *Stroke*. 2008;39(4):1103-8 (PMID: 18309169, PMCID: PMC2650384).
- 32) **Taub PR**, Daniels LB, Maisel AS. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation. *Heart Fail Clin*. 2009;5(2):169-75 (PMID: 19249686).
- 33) **Taub PR**, Gabbai-Saldate P, Maisel A. Biomarkers of heart failure. *Congest Heart Fail*. 2010;16 Suppl 1:S19-24 (PMID: 20653707).
- 34) **Taub PR**, Fields J, Wu AH, Miss J, Lawton M, Smith WS, Young WL, Zaroff JG, Ko NU. Elevated BNP is Associated with vasospasm-independent cerebral infarction following aneurysmal subarachnoid hemorrhage. *Neurocritical Care* 2011;15:13-18. (PMID: 21479679, PMCID: 3133817).
- 35) Xue Y*, **Taub PR**, Fard A, Maisel AS. Hypervolemic and optivolemic natriuretic peptides in acute heart failure. *Contrib Nephrol* 2011;171:74-9. (PMID: 21625093).
- 36) Xue Y*, **Taub PR**, Iqbal N, Fard A, Wentworth B, Redwine L, Clopton P, Stein M, Maisel A. Cardiac biomarkers, mortality, and post-traumatic stress disorder in military veterans. *Am J Cardiol*. 2012;109(8):1215-8 (PMID: 22305506).
- 37) **Taub PR**, Borden KC, Fard A, Maisel A. Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome. *Expert Rev Cardiovasc Ther*. 2012;10(5):657-67 (PMID: 22651841, PMCID: PMC4060800).
- 38) Prasain JK, Arabshahi A, **Taub PR**, Sweeney S, Moore R, Sharer JD, Barnes S. Simultaneous quantification of F2-isoprostanes and prostaglandins in human urine by liquid chromatography tandem-mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2013;913-914:161-8 (PMID: 23314354, PMCID: PMC3779072).
- 39) Wentworth BA*, Stein MB, Redwine LS, Xue Y, **Taub PR**, Clopton P, Nayak KR, Maisel AS. Post-traumatic stress disorder: a fast track to premature cardiovascular disease? *Cardiol Rev*. 2013;21(1):16-22 (PMID: 22717656).
- 40) Xue Y*, **Taub PR***, Iqbal N, Fard A, Clopton P, Maisel A. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure. *Eur J Heart Fail* 2013;15:1343-9 (PMID: 23887059). *co-first author
- 41) Maisel A, Barnard D, Jaski B, Frivold G, Marais J, Azer M, Miyamoto MI, Lombardo D, Kelsay D, Borden K, Iqbal N, **Taub PR**, Kupfer K, Clopton P, Greenberg B. Primary results of the HABIT Trial (heart failure assessment with BNP in the home). *J Am Coll Cardiol*. 2013;61(16):1726-35 (PMID: 23500322).
- 42) Tokman S*, Barnett CF, Jarlsberg LG, **Taub PR**, den Boon S, Davis JL, Cattamanchi A, Worodria W, Maisel A, Huang L. International HIV-Associated Opportunistic Pneumonias (IHOP) Study Group. Procalcitonin predicts mortality in HIV-infected Ugandan adults with lower respiratory tract infections. *Respirology*. 2014 Apr;19(3):382-8 (PMID: 24460728, PMCID: PMC4276722).
- 43) Shah KS*, **Taub PR**, Patel M, Rehfeldt M, Struck J, Clopton P, Mehta RL, Maisel AS. Proenkephalin predicts acute kidney injury in cardiac surgery patients. *Clin Nephrol*. 2015;83(1):29-35 (PMID: 25512100).
- 44) Maisel AS, Shah KS, Barnard D, Jaski B, Frivold G, Marais J, Azer M, Miyamoto MI, Lombardo D, Kelsay D, Iqbal N, **Taub PR**, Kupfer K, Lee E, Clopton P, Zile M, Greenberg B. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial. *J Card Fail*. 2016;22(4):283-93 (PMID: 26433086).
- 45) Maisel AS, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müller GA, Birkhahn R, Clopton P, **Taub P**, Vilke GM, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Murray PT. Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations: The AKINESIS Study. *J Am Coll Cardiol*. 2016; 68(13):1420-31 (PMID: 27659464).
- 46) Swiatkiewicz I*, **Taub PR**. The usefulness of C-reactive protein for the prediction of post-infarct left ventricular systolic dysfunction and heart failure. *Kardiol Pol*. 2018;76(5):821-829 (PMID: 29633232).
- 47) Murray PT, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müller GA, Birkhahn R, Horiuchi Y, Clopton P, **Taub P**, Vilke GM, Barnett O, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Maisel A. Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary findings for urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic heart failure Study (AKINESIS). *J Card Fail*. 2019;25(8):654-665 (PMID: 31128242).

- 48) Wettersten N*, Horiuchi Y, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, **Taub P**, Vilke GM, Barnett O, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Murray PT, Maisel A. B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. *Eur J Heart Fail*. 2019;21(12):1553-1560 (PMID: 31769140).
- 49) Wettersten N*, Horiuchi Y, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, **Taub P**, Vilke GM, Barnett O, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Maisel A, Murray PT. Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study. *Eur J Heart Fail*. 2020 Feb;22(2):251-263 (PMID: 31863682).
- 50) Świątkiewicz I*, Magielski P, Kubica J, Zadourian A, DeMaria AN, **Taub PR**. Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure. *Int J Mol Sci*. 2020;21(3):807. (PMID: 31991903)
- 51) Horiuchi Y, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, **Taub P**, Vilke GM, Barnett O, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Maisel A, Murray PT. Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure. *Am J Cardiol*. 2021; (PMID: 33617811)
- 52) Horiuchi YU, Wettersten N, Veldhuisen DJV, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, **Taub P**, Vilke GM, Barnett O, McDONALD K, Mahon N, Nuñez J, Briguori C, Passino C, Maisel A, Murray PT. Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. *J Card Fail*. 2021 May;27(5):533-541. (PMID: 33296713)
- 53) Horiuchi Y, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, **Taub P**, Vilke GM, Barnett O, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Duff S, Maisel A, Murray PT. Decongestion, kidney injury and prognosis in patients with acute heart failure. *Int J Cardiol*. 2022 Feb 21:S0167-5273(22)00261-3. (PMID: 35202737)
- 54) Wettersten N, Duff S, Horiuchi Y, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, **Taub P**, Vilke GM, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Maisel A, Murray PT, Ix JH. Implications of worsening renal function before hospitalization for acute heart failure. *ESC Heart Fail*. 2022 Nov 3. doi: 10.1002/ehf2.14221. (PMID: 36325747)
- 55) Horiuchi Y, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, **Taub P**, Vilke GM, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Duff S, Maisel A, Murray PT. Galectin-3, acute kidney injury and myocardial damage in patients with acute heart failure. *J Card Fail*. 2022 Nov 1:S1071-9164(22)01171-X. doi:10.1016/j.cardfail.2022.09.017, (PMID: 36332898)

5. Other Publications in Chronological Order

- 56) Scarrow A, **Rajendran PR**, William Welch. Glioblastoma multiforme of the conus medullaris. *Clin Neurol Neurosurg*. 2000;102:166-9 (PMID: 10996716).
- 57) Scarrow A, **Rajendran PR**, Donald M. Metastatic prostate adenocarcinoma of the dura mater. *Br J Neurosurg*. 2000;14:473-5 (PMID: 11198774).
- 58) Hersh BP, **Rajendran PR**, Battinelli D, Parkinsonism as the presenting manifestation of HIV infection: improvement on HAART. *Neurology*. 2001;56:278-9 (PMID: 11160977).
- 59) **Rajendran PR**. The internet: ushering in a new era of medicine. *JAMA*. 2001;285:804 (PMID: 11176920).
- 60) **Rajendran PR**, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson's disease. *Neurology*. 2001;57:790-4 (PMID: 11552005).
- 61) **Rajendran PR**. Ethical issues involved in disclosing medical errors. *JAMA*. 2001;286(9):1078 (PMID: 11559295).
- 62) **Rajendran PR**, Molitor J. Resolution of hypertensive encephalopathy and scleroderma renal crisis with an angiotensin receptor blocker. *J Clin Rheumatol*. 2005;11:205-8 (PMID: 16357757).
- 63) Yarlaga S. **Rajendran PR**, Miss J, Banki N, Kopelnik A, Ko N, Gelb A, Lawton M, Smith W, Young W, Zaroff J. Cardiovascular predictors of inpatient mortality after subarachnoid hemorrhage. *Neurocrit Care*. 2006;5(2):102-7 (PMID: 17099255).
- 64) **Taub PR**, Higginbotham E, Henry RR. Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes. *Curr Cardiol Rep*. 2013;2:332 (PMID: 23314689).

- 65) Higginbotham, E*, **Taub PR**. Cardiovascular benefits of dark chocolate? *Curr Treat Options Cardiovasc Med*. 2015;(12):54 (PMID: 26456559).
- 66) Aggarwal M, Devries S, Freeman AM, Ostfeld R, Gaggin H, **Taub P**, Rzeszut AK, Allen K, Conti RC. The Deficit of Nutrition Education of Physicians. *Am J Med*. 2018;131(4):339-345 (PMID: 29269228).
- 67) Henry RR, Müller-Wieland D, **Taub PR**, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN. Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. *Diabetes Obes Metab*. 2018;20(7):1632-1641 (PMID: 29493859).
- 68) Freeman AM, **Taub PR**, Lo HC, Ornish D. Intensive Cardiac Rehabilitation: an Underutilized Resource. *Curr Cardiol Rep*. 2019;21(4):19 (PMID: 30828747).
- 69) Modestino AE, Skowronski EA, Pruitt C, **Taub PR**, Herbst K, Schmid-Schönbein GW, Heller MJ, Mills PJ. Elevated Resting and Postprandial Digestive Proteolytic Activity in Peripheral Blood of Individuals With Type-2 Diabetes Mellitus, With Uncontrolled Cleavage of Insulin Receptors. *J Am Coll Nutr*. 2019; 38(6):485-492 (PMID: 30964398).
- 70) Mills PJ, **Taub PR**, Lunde O, Pung MA, Wilson K, Pruitt C, Rutledge T, Maisel A, Greenberg BH. Depressive symptoms in asymptomatic stage B heart failure with Type II diabetic mellitus. *Clin Cardiol*. 2019;42(6):637-643 (PMID: 31017303, PMCID: PMC6553353).
- 71) Sands BE, **Taub PR**, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, Pedersen RD, Chan G, Nduaka CI, Quirk D, Salese L, Su C, Feagan BG. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. *Clin Gastroenterol Hepatol*. 2020 Jan;18(1):123-132.e3. PMID: 31077827.
- 72) Wilkinson MJ*, Zadourian A, **Taub PR**. Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. *Am J Card*. 2019; 124(1):S3-S11 (PMID: 31741438).
- 73) Saiz J, Pung MA, Wilson KL, Pruitt C, Rutledge T, Redwine L, **Taub PR**, Greenberg BH, Mills PJ. Is Belonging to a Religious Organization Enough? Differences in Religious Affiliation Versus Self-ratings of Spirituality on Behavioral and Psychological Variables in Individuals With Heart Failure. *Healthcare (Basel)*. 2020;8(2):E129 (PMID: 32397220).
- 74) Khera A, Baum SJ, Gluckman TJ, Gulati M, Martin SS, Michos ED, Navar AM, **Taub PR**, Toth PP, Virani SS, Wong ND, Shapiro MD. Continuity of Care and Outpatient Management for Patients with and at High Risk for Cardiovascular Disease during the COVID-19 Pandemic: A Scientific Statement from the American Society for Preventive Cardiology. *American Journal of Preventive Cardiology*. 2020:100009 (PMCID: PMC7194073).
- 75) D'Souza MS*, Dong TA, Ragazzo G, Dhindsa DS, Mehta A, Sandesara PB, Freeman AM, **Taub P**, Sperling LS. From Fad to Fact: Evaluating the Impact of Emerging Diets on the Prevention of Cardiovascular Disease. *Am J Med*. 2020 Oct;133(10):1126-1134. Epub 2020 Jun 19. Review. (PMID: 32569590).
- 76) Hsu JC, Darden D, Alegre M, Birgersdotter-Green U, Feld GK, Hoffmayer KS, Han F, Krummen D, Raissi F, Ho G, **Taub PR**, Urey MA, Adler E. Effect of closed loop stimulation versus accelerometer on outcomes with cardiac resynchronization therapy: the CLASS trial. *J Interv Card Electrophysiol*. 2021 Sep;61(3):479-485. PMID: 32757086.
- 77) Sands BE, Colombel JF, Ha C, Farnier M, Armuzzi A, Quirk D, Friedman GS, Kwok K, Salese L, Su C, **Taub PR**. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. *Inflamm Bowel Dis*. 2021 May 17;27(6):797-808. PMID: 32870265.
- 78) Chindhy S*, **Taub PR**, Lavie CJ, Shen J. Current challenges in cardiac rehabilitation: strategies to overcome social factors and attendance barriers. *Expert Rev Cardiovasc Ther*. 2020 Sep 14;:1-13. (PMID: 32885702).
- 79) McCormick D, Bhatt DL, Bays HE, **Taub PR**, Caldwell KA, Guerin CK, Steinhoff J, Ahmad Z, Singh R, Moreo K, Carter J, Heggen CL, Sapir T. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model. *J Manag Care Spec Pharm*. 2020 Dec;26(12):1517-1528. (PMID: 33251993).
- 80) Atar D, Jukema, J, Molemans B, **Taub PR**, Goto S, Mach F, CerezoOlmos C, Underberg J, Keech A, Tokgozoglu L, Bonaca M. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? *Atherosclerosis*. 2021 (PMID: 33476944).
- 81) Epstein E*, Rosander A, Pazargadi A, **Taub P**. Cardiac Rehab for Functional Improvement. *Curr Heart Fail Rep*. 2020 Aug;17(4):161-170. (PMID: 32514659).
- 82) Mkrtchyan GV, Abdelmohsen K, Andreux P, Bagdonaite I, Barzilai N, Brunak S, Cabreiro F, de Cabo R, Campisi J, Cuervo AM, Demaria M, Ewald CY, Fang EF, Faragher R, Ferrucci L, Freund A, Silva-García CG, Georgievskaya A, Gladyshev VN, Glass DJ, Gorbunova V, de Grey A, He WW, Hoeijmakers J, Hoffmann E,

- Horvath S, Houtkooper RH, Jensen MK, Jensen MB, Kane A, Kassem M, de Keizer P, Kennedy B, Karsenty G, Lamming DW, Lee KF, MacAulay N, Mamoshina P, Mellon J, Molenaars M, Moskalev A, Mund A, Niedernhofer L, Osborne B, Pak HH, Parkhitko A, Raimundo N, Rando TA, Rasmussen LJ, Reis C, Riedel CG, Franco-Romero A, Schumacher B, Sinclair DA, Suh Y, **Taub PR**, Toiber D, Treebak JT, Valenzano DR, Verdin E, Vijg J, Young S, Zhang L, Bakula D, Zhavoronkov A, Scheibye-Knudsen M. ARDD 2020: from aging mechanisms to interventions. *Aging (Albany NY)*. 2020 Dec 30;12(24):24484-24503. (PMID: 33378272).
- 83) Epstein E*, Patel N, Maysent K, **Taub PR**. Cardiac Rehab in the COVID Era and Beyond: mHealth and Other Novel Opportunities. *Curr Cardiol Rep*. 2021. (PMID: 33704611)
- 84) Epstein E*, Maisel S, Maysent K, **Taub PR**. Cardiac rehabilitation for coronary artery disease: latest updates. *Curr Opin Cardiol*. 2021 Sep 1;36(5):556-564. (PMID: 34397462)
- 85) Lee AC, Castaneda G, Li WT, Chen C, Shende N, Chakladar J, **Taub PR**, Chang EY, Ongkeko WM. COVID-19 Severity Potentially Modulated by Cardiovascular-Disease-Associated Immune Dysregulation. *Viruses*. 2021. PMID: (34071557)
- 86) Aroda VR, **Taub PR**, Stanton AM. Diabetes With Cardiomyopathy: At the Juncture of Knowledge and Prevention. *J Am Coll Cardiol*. 2021 Oct 19;78(16):1599-1602. (PMID: 34649697)
- 87) Bays HE, **Taub PR**, Epstein E*, Michos ED, Ferraro RA, Bailey AL, Kelli HM, Ferdinand KC, Echols MR, Weintraub H, Bostrom J, Johnson HM, Hoppe KK, Shapiro MD, German CA, Virani SS, Hussain A, Ballantyne CM, Agha AM, Toth PP. Ten things to know about ten cardiovascular disease risk factors. *Am J Prev Cardiol*. 2021 Jan 23;5:100149. (PMID: 34327491)
- 88) Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, **Taub PR**, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. *J Diabetes Complications*. 2021 Dec 7:108101. Epub ahead of print. (PMID: 34922811)
- 89) Xu I*, **Taub PR**. Baseline testosterone level may modulate statin efficacy. *Coron Artery Dis*. 2021 Dec 1;32(8):713-714. (PMID: 33826543)
- 90) Świątkiewicz I*, Di Somma S, De Fazio L, Mazzilli V, **Taub PR**. Effectiveness of Intensive Cardiac Rehabilitation in High-Risk Patients with Cardiovascular Disease in Real-World Practice. *Nutrients*. 2021 Oct 29;13(11):3883. (PMID: 34836144)
- 91) Lee AC, Li WT, Apostol L, Ma J, **Taub PR**, Chang EY, Rajasekaran M, Ongkeko WM. Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: A systematic-review and meta-analysis. *Comput Struct Biotechnol J*. 2021;19:3755-3764. (PMID: 34221254)
- 92) Wettersten N, Horiuchi Y, van Veldhuisen DJ, Ix JH, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, **Taub P**, Vilke GM, Duff S, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Maisel A, Murray PT. Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure. *Eur J Heart Fail*. 2021;23(7):1122-1130. (PMID: 33788989)
- 93) You S, Masutani EM, Alley MT, Vasanawala SS, **Taub PR**, Liau J, Roberts AC, Hsiao A. Deep Learning Automated Background Phase Error Correction for Abdominopelvic 4D Flow MRI. *Radiology*. 2021; 30:211270. (PMID: 34846200)
- 94) Kianoush S, Al Rifai M, Patel J, George J, Gulati M, **Taub P**, Moran T, Shapiro MD, Agarwala A, Ullah W, Lavie CJ, Bittner V, Ballantyne CM, Virani SS. Association of participation in Cardiac Rehabilitation with Social Vulnerability Index: The behavioral risk factor surveillance system. *Prog Cardiovasc Dis*. 2022; 16:S0033-0620(22)00021-4. (PMID: 35182577)
- 95) Ormiston CK*, Rosander A, **Taub PR**. Heart-Healthy Diets and the Cardiometabolic Jackpot. *Med Clin North Am*. 2022;106(2):235-247. PMID: 35227427
- 96) Sykes AV*, Patel N, Lee D, **Taub PR**. Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment. *Curr Cardiol Rep*. 2022;24(11):1647-1655. (PMID: 36001215)
- 97) Wettersten N*, Duff S, Horiuchi Y, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, **Taub P**, Vilke GM, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Maisel A, Murray PT, Ix JH. Implications of worsening renal function before hospitalization for acute heart failure. *ESC Heart Fail*. 2023 Feb;10(1):532-541 (PMID: 36325747)

- 98) Chiou TT*, Tomasi K, **Taub PR**, Wilkinson MJ. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic. *J Clin Lipidol*. 2022 Nov 1:S1933-2874(22)00292-6. doi: 10.1016/j.jacl.2022.10.009. (PMID: 36371372)
- 99) Sykes AV*, Sonners C, Schmickl CN, Raphelson J, Swiatkiewicz I, Roberts E, Feldman E, Malhotra A, **Taub PR**. The Impact of Underlying Obstructive Sleep Apnea Treatment on Exercise Capacity in Patients With Pulmonary Hypertension Undergoing a Cardiac Rehabilitation Program. *J Cardiopulm Rehabil Prev*. 2022 Dec 14;. Epub ahead of print. (PMID: 36729594.)
- 100) Sykes AV*, Epstein E, Abolhassan Choubdar P, **Taub PR**. 2 Cases of Elusive Left Ventricular Outflow Tract Gradient. *JACC Case Rep*. 2022 ; 4(21): 1404–1408. (PMID: 36388718)\
- 101) Sonners C*, Schmickl CN, Raphelson J, Sykes AV, Roberts EG, Swiatkiewicz I, Malhotra A, **Taub PR**. The impact of obstructive sleep apnea on exercise capacity in a cardiac rehabilitation program. *Sleep Breath*. 2022 Sep 29. doi: 10.1007/s11325-022-02704-0. (PMID: 36173506)
- 102) Wilkinson MJ, Xu I, Vasudevan RS, You H, Xu R, **Taub PR**. Trends in LDL-C following coronary angiography involving assessment by fractional flow reserve in obstructive vs non-obstructive coronary artery disease. *Am J Prev Cardiol*. 2023;13;13:100473. (PMID: 36865903)

Complete List of Published Work in My Bibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/pam.taub.1/bibliography/public/>

Textbook

Wilkinson M, Garshick M, **Taub PR** (editors) *Nutritional and Dietary Approaches to the Prevention and Treatment of Cardiovascular Disease*. 1st ed., Springer.

Selected Book Chapters

1. Kevin Shah, **Pam R. Taub**, Alan Maisel (2011). Biomarkers in acute heart failure. In: Tubaro M, Danchin N, Filippatos G, Goldstein P, Vranckx P, Zahger D, eds. *European Society of Cardiology Textbook of Intensive and Acute Cardiac Care* (pp. 335-245). Oxford: Oxford University Press.
2. Kabir Singh, **Pam R. Taub**, Alan Maisel (2011). Biomarkers. In: Baliga R (Ed), *Cardiology Review* (pp. 26-36). New York: McGraw Hill.
3. Hannah C. Lo, Aryana Pazargadi Iwona Świątkiewicz, **Pam R. Taub**. (2021). Secondary Prevention and Cardiac Rehabilitation. In *ASPC Manual of Preventive Cardiology* (pp. 673-703). Springer, Cham.

Granted Patents

1. **U.S. Patent 8,648,059**. “Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling.”
Inventors: **Pam R. Taub**, Francisco Villareal, Katrina Yamazaki, Alan Maisel
Filed: March 14, 2008. **Issued: 2/11/14**
2. **US Patent 10,052,316**. “Methods and compositions for treatment of mitochondrial toxicity.”
Inventors: **Pam R. Taub**, Francisco Villarreal, Alan Maisel, George F. Schreiner, Guillermo M. Ceballos
Filed: 06/05/12. **Issued: 8/21/18**

*Based on these patents and publications related to epicatechin, I co-founded a start-up company Epirium Bio (www.epirium.com), which is developing therapeutics that promote mitochondrial biogenesis and function.

SELECTED HONORS AND AWARDS

- | | |
|------|--|
| 2000 | G. Milton Shy Award in Clinical Neurology from the American Academy of Neurology for best clinical research paper. |
| 2002 | American Medical Association Hammond Scholarship for outstanding achievement in medical journalism. |
| 2003 | Boston Medical Center/Boston City Hospital Student Prize for top performance in clinical rotations. |
| 2003 | Boston University School of Medicine Bertha Curtis Award for excellence in clinical medicine. |
| 2003 | American Academy of Neurology Medical Student Prize for Excellence in Neurology. |
| 2003 | Alpha Omega Alpha (Medical Honor Society) Member. |
| 2009 | American College of Cardiology Foundation/Merck Research Grant (one of four cardiology fellows nationally awarded this grant). |
| 2009 | American Society of Nuclear Cardiology/Astellas Award. |

2009	American Heart Association Women in Cardiology Training Award for Excellence.
2009	American College of Cardiology Foundation/Bristol-Meyers Squibb Travel Award.
2022	San Diego County Medical Society “Top Doctors Award” (selected by peers in my specialty for years 2011, 2015, 2016, 2017, 2018, 2021, 2022).

PROFESSIONAL COMMITTEE SERVICE

- Editor of Medical Student Section of Journal of the American Medical Association (JAMA), 2000-2002
- American College of Cardiology Nutrition Workgroup Member, 2016-Present
- American College of Cardiology Testing Materials Development Committee Member, 2018-2022
- American College of Cardiology/Medscape Steering Committee Member for the Center of Excellence on Cardiovascular Risk Reduction, 2018- Present
- American College of Cardiology Chair of Transforming Cardiovascular Risk in Diabetes Educational Initiative, 2020-present
- Chair of Cardiometabolic Health Congress on The Intersection of Women's Reproductive Diseases & Cardiometabolic Health: Implications for Risk Assessment and Management, 2020-2021
[Cardiometabolic Health and Reproductive Diseases - CMHC Live Online](#)
- Co-Chair of 2022 and 2023 Cardiometabolic Health Congress Women's Cardiometabolic Health and Wellness Masterclass : [Womens Cardiometabolic Health and Wellness Masterclass | Cardiometabolic Health Congress](#)
- American College of Cardiology Writing Group Member on Coronary Revascularization Appropriate Use Criteria, 2020-2022
- American Society of Preventive Cardiology Board Member, 2018-2024
- American College of Cardiology Prevention Leadership Council 2020- 2023
- American College of Cardiology Annual Meeting Program Committee Member, 2020, 2021,2022
- American College of Cardiology Annual Meeting Abstract Review Capitan, 2020, 2021, 2022, 2023
- American Heart Association Women in Cardiology Leadership Committee, 2019-2022
- Ad Hoc Reviewer NHLBI Clinical Integrative Cardiovascular and Hematological Sciences Study section (CCHS) 2022
- Woman As One (Core Committee Member) 2023

SELECTED PRESENTATIONS (from over 150) FROM NATIONAL AND INTERNATIONAL MEETINGS

- “*Cardiac Rehabilitation: Current and Future Directions*” Baylor College of Medicine and Texas Heart Institute Grand Rounds. Houston, TX (April 2016).
- “*Treating Hypercholesterolemia Using PCSK9 Inhibitors: How Low Should You Go?*” American Academy of Clinical Endocrinology. Orlando, FL (May 2016).
- “*Expert Debate on CVD Risk Reduction in the Cardiometabolic Patient*” National Lipid Association Meeting. Las Vegas, NV (April 2018).
- “*Cardiovascular Complications of Pregnancy*” 13th Annual Cardiometabolic Health Congress. Boston, MA (October 2018).
- “*PCSK9 Inhibition in ASCVD Patients*” National Lipid Association Meeting. Portland, OR (February 2019)
- “*Barriers to Cardiac Rehabilitation: How Do We Overcome Issues With Adherence and Cost?*” and “*The Mind-Body-Heart Connection: What's the evidence?*” American College of Cardiology Annual Meeting. New Orleans, LA (March 2019).
- “*PCSK9 Inhibitors*” American College of Physicians Annual Meeting. Philadelphia, PA (April 2019).
- “*Impact of Pregnancy on CV Risk Factors and ASCVD Risk*” Cardiometabolic Health West Congress. Phoenix, AZ (May 2019).
- “*Criticality of LDL-C Lowering: A Focus on New Cholesterol Management Guidelines*” Pri Med West. Anaheim, CA (May 2019).
- “*The Role of PCSK9 Inhibitors in High Risk Patient Groups*” Heart in Diabetes Meeting. Philadelphia, PA (July 2019).
- “*Rebranding and Rehabilitating Cardiac Rehabilitation in 2019*” and “*Making Prevention Pay*” American Society of Preventive Cardiology Annual Meeting. San Antonio, TX (July 2019).
- “*Cardiac Rehabilitation Program Including Diet, Relaxation and Physical Activity*” Great Italy VIII International Meeting. Acciaroli, Italy (September 2019).

- “*Lifestyle Strategies for Cardiometabolic Disease*” Grand Rounds at Georgetown University/Washington Hospital Center. Washington DC (October 2019).
- “*Sneak Peek at Data from PRIME & AMCP Focus Groups in PCSK9i Management*” The Academy of Managed Care Pharmacy Annual Meeting. National Harbor, MD (October 2019).
- “Disease State Symposium: The Continuum of Heart Failure” American Heart Association Annual Meeting Philadelphia, PA (November 2019).
- “*Patient with Metabolic Syndrome Lifestyle Strategies Including Intermittent Fasting*” and “*Patient with Mild Elevation in Triglycerides and CAD/DM*” American College of Cardiology International Cardiometabolic Summit. Mumbai, India (February 2020).
- “*Clinical Management of Diabetes with Cardiomyopathy—Current Management, Future Directions*” American Diabetes Association Annual Meeting New Orleans, LA (June 2022)
- “*Lipid Management in high risk patients*” 3rd Annual American College of Cardiology/American Diabetes Association Latin America Cardiometabolic Disease Forum. Oaxaca, Mexico (July 2022)

Selected Media Appearances

- 1) NPR 2021:
<https://www.npr.org/sections/health-shots/2021/05/22/996533041/after-months-of-a-racing-heart-and-burning-feet-a-covid-long-hauler-gets-a-diagn>
- 2) The Today Show 2021:
[Living with POTS, a long-hauler symptom of COVID-19 - TODAY](#)
- 3) Dr. Oz Show 2018:
[Facebook Live | Facebook](#)
- 4) Wall Street Journal 2018:
[A Diet Strategy That Counts Time, Not Calories - WSJ](#)

ONGOING RESEARCH SUPPORT

- NIH R01 DK118278-01 (PI: Taub, PR) 07/01/2018 – 09/30/2023
 “Impact of time-restricted eating (TRE) on glucose homeostasis and mitochondrial function in patients with metabolic syndrome – The TIMET Study” \$5,886,704
 The goal of this study is to examine the impact of time-restricted eating in patients with metabolic syndrome.
 Role: Principal Investigator
- Larry Hillblom Foundation Network Grant (PI: Taub, PR) 01/01/2022 – 12/31/2025
 “Feasibility and Efficacy of Time-Restricted Eating in Diabetes Management” \$1,200,000
 The goal of this study is to examine the safety and efficacy of time restricted eating in patients with Type II diabetes.
 Role: Principal Investigator
- NIH R01 HL136407 (PI: Mills, PJ) 01/15/2018 – 12/31/2023
 “Increasing adherence to guideline-based exercise therapy for chronic heart failure” \$3,086,340
 The goal of this study is to optimize adherence to exercise regimens in heart failure (HF), improve physical functioning and quality of life, and reduce morbidity.
 Role: Co-Investigator
- Applied Therapeutics (PI: Taub, PR) 05/01/2020 - 12/31/2023
 “Prevalence of diabetic cardiomyopathy and its association with heart failure in real-world practice” \$142,480
 The goal of this study is to determine the prevalence of diabetic cardiomyopathy among patients with T2DM at UCSD and to evaluate prevalence and severity of symptomatic HF in this population of patients.
 Role: Principal Investigator

COMPLETED RESEARCH SUPPORT

- Amgen (PI: Wilkinson, MJ) 05/01/2020 - 12/31/2022
 "Comparison of lipid-lowering pharmacotherapy utilization in patients with hemodynamically significant coronary artery disease by FFR, iFR, or CT-FFR versus patients with non-obstructive coronary artery disease" \$221,274
 The goal of this study is to examine the use of statins and non-statin lipid lowering therapies after performance of FFR, iFR, or CT-FFR via retrospective review of clinical data.
 Role: Co-Investigator
- Department of Homeland Security/FEMA (Co-PI: Taub, PR) 12/20/2017 – 12/20/2020
 "Optimizing circadian rhythms by regulating eating patterns to reduce cardiometabolic disease risk among firefighters – The Healthy Heroes Study" \$2,384,523
 The goal of this study is to determine the effectiveness of time-restricted eating in firefighters to reduce their cardiometabolic disease risk.
 Role: Co-Principal Investigator
- American Heart Association (PI: Taub, PR) 01/01/2015 – 06/01/2021
 National Scientist Development Grant
 "Effects of epicatechin on patients with statin-induced mitochondrial dysfunction and impaired exercise capacity"
 \$308,000
 The goal of this project is to assess the effects of epicatechin on patients with statin-induced mitochondrial dysfunction and impaired exercise capacity.
 Role: Principal Investigator
- GW140045 (PI: Golomb, BA) 08/01/2015 – 12/30/2020
 Department of Defense
 "Muscle Mitochondrial Assessments in Gulf War Illness" \$1,085,000
 The goal of this project is to understand mechanisms of mitochondrial dysfunction in military veterans with gulf war syndrome.
 Role: Co-Investigator
- Amgen (PI: Taub, PR) 09/01/2017 – 07/30/2020
 "Effect of Ivabradine on Patients with Postural orthostatic tachycardia syndrome (a double-blind placebo-controlled trial)"
 The goal of this study is to investigate the effect of Ivabradine on patients with postural orthostatic tachycardia syndrome.
 Role: Principal Investigator
- UCSD Public Health Institute (PI: Taub, PR) 07/01/2016 – 03/31/2018
 "The impact of time restricted feeding (TRF) in improving the health of patients with metabolic syndrome"
 The goal of this study is to determine if restricting the number of hours of food consumption will improve the overall cardiometabolic health parameters in patients with metabolic syndrome.
 Role: Principal Investigator
- Philips (PI: Taub, PR) 09/01/2016 – 9/31/2017
 Philips Usability Study
 The goal of this study is to determine the effectiveness of the Philips smartphone application in engaging patients to take an active role in monitoring their health and improving their overall health.
 Role: Principal Investigator
- NIH R01 DK098717 (PI: Villarreal, FJ) 03/10/2014 – 12/31/2017
 "Epicatechin and Derivatives to Preserve Muscle Structure Function in Diabetes"
 The goal of this project is to assess effects of epicatechin and derivatives in preserving muscle structure function in patients with diabetes.
 Role: Co-Investigator
- NIH R21 AT007600 (PI: Redwine, LS) 09/30/2013 – 06/30/2016

“Developing a mindfulness movement intervention program for post-myocardial infarction patients”

The goal of this project is to assess effects of tai chi on cardiac biomarkers and quality of life measures in patients after myocardial infarction.

Role: Co-Investigator

NIH R21 AG047326 (PI: Villarreal, FJ)

09/15/2015 – 08/31/2016

“Epicatechin treatment for sarcopenia”

The goal of this project is to examine the effects of epicatechin for the treatment of sarcopenia.

Role: Co-Investigator

NIH R21 AT008033 (PI: Mills, PJ)

09/01/2014 – 08/31/2016

“Gratitude in post MI patients’ effects on health-related mood and clinical outcome”

The goal of this project is to assess how gratitude impacts health related mood and clinical outcomes in patients after myocardial infarction.

Role: Co-Investigator

NIDDK R24 11-0708 (PI: Villarreal, FJ)

08/2011 – 08/2012

“Targeting cellular bioenergetics for the prevention and treatment of diabetes.”

The major goals of this grant are to examine the molecular effects of epicatechin in the prevention and treatment of diabetes.

Role: Co-Investigator

Hershey Company Clinical Trial Research Grant (PI: Taub, PR)

09/2011 – 08/2013

The goal of this project is to assess the effects of epicatechin enriched dark chocolate on mitochondrial function and exercise capacity in patients with heart failure and diabetes and in normal sedentary individuals.

Role: Principal Investigator

NIDDK P30DK079337 O’Brien Pilot and Feasibility Grant (PI: Taub, PR)

08/2010 – 08/2012

The major goals of this project are to evaluate the use of exosome biomarkers for early diagnosis of patients with acute kidney injury.

Role: Principal Investigator

Brahms Thermo Fisher Research Grant (PI: Taub, PR)

07/2010 – 07/2012

The major goals of this project are to examine the usefulness of the biomarker MR-PROADM for prognosis in patients with heart failure and the use of the biomarker procalcitonin in differentiating between different types of pneumonias.

Role: Principal Investigator

American College of Cardiology/Merck Research Grant (PI: Taub, PR)

07/2009 – 07/2010

The major goals of this grant are to examine the effects of epicatechin on cultures of human skeletal muscle cells.

Role: Principal Investigator

Hershey Company Research Grant (PI: Taub, PR)

12/2009 – 12/2010

The goal of this project is to assess the effects of epicatechin on patients with heart failure and diabetes.

Role: Principal Investigator